As Testosterone Treatment Lawsuits Move Forward in U.S., European Regulators Weigh in On Possible Heart Risks, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating testosterone lawsuits on behalf of men who suffered heart attacks, strokes and other cardiovascular problems, allegedly due to their use of low testosterone therapies like AndroGel.

Free Case Review
This report comes as hundreds of men in the U.S. pursue testosterone lawsuits due to heart-related injuries that were allegedly caused by testosterone replacement therapy. We agree with the EMA’s conclusion that this issue requires more researc

As testosterone treatment lawsuits (http://www.drugbot.com/testosterone/lawsuit/) continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that European health regulators have weighed in on the cardiovascular risks potentially associated with prescription low testosterone therapies. In a report issued on October 10th, the European Medicines Agency (EMA) said that its review had found that the evidence linking testosterone medications to heart attacks, strokes and other cardiovascular problems was inconsistent, and that further study of the matter is needed. However, the agency also stressed that testosterone replacement drugs should only be used in men who truly suffer from hypogonadism (low testosterone), and that the European Union has not authorized the medications for use in healthy, older men.*

“This report comes as hundreds of men in the U.S. pursue testosterone lawsuits due to heart-related injuries that were allegedly caused by testosterone replacement therapy. We agree with the EMA’s conclusion that this issue requires more research,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating legal claims on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other life-threatening heart problems due to their use of prescription testosterone medications.

Testosterone Lawsuits
Testosterone gels, patches and injections are approved to treat low testosterone (hypogonadism) in men who suffer from the condition due to an underlying medical issue. Medications in this class include:* *

  •     Axiron
  •     AndroDerm
  •     AndroGel
  •     Bio-T Gel
  •     Delatestryl
  •     Depo-Testosterone
  •     Foresta
  •     Striant
  •     Testopel
  •     Testim

In January 2014, the U.S. Food & Drug Administration (FDA) announced it was investigating the cardiovascular risks associated with low testosterone therapy. Since then, a panel of FDA advisors recommended that the drugs’ labels be revised to make clear they have not been shown to lessen low libido, fatigue, muscle loss and other age-related symptoms. They also recommended that the manufacturers of testosterone replacement therapies be required to conduct studies of their cardiovascular side effects.***

Court records indicate that at least 200 testosterone lawsuits are now pending in a federal multidistrict litigation underway in U.S. District Court, Northern District of Illinois. All of the claims were filed on behalf of men who allegedly suffered life-threatening cardiovascular events due to their use of drugs like AndroGel, Axiron and Testim. Among other things, the plaintiffs involved in this litigation allege that the manufacturers of low testosterone therapies failed to warn doctors and patients about their potential risks, and concealed those dangers from the public. The lawsuits further claim that misleading marketing induced many healthy men to use testosterone treatments to mitigate low libido, fatigue and other age-related symptoms, even though they had no medical need for the drugs. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

Men who allegedly suffered serious heart side effects due to their use of prescription testosterone therapies may be entitled to compensation from the manufacturers of these mediations. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*ema.europa.eu/docs/en_GB/document_library/Referrals_document/Testosterone_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500175213.pdf, EMA, October 10, 2014
**accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&searchTerm=testosterone&Search_Button=Submit, FDA
***reuters.com/article/2014/09/17/us-usa-health-testosterone-idUSKBN0HC2C320140917, Reuters, September 18, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP

10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.drugbot.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
DrugBot.com
+1 800-511-5092
Email >
Follow us on
Visit website